IL-1RN and IL-1B gene polymorphisms and cerebral hemorrhagic events after traumatic brain injury

Neurology

Volumn 65, Issue 7, 2005, Pages 1077-1082

  Hadjigeorgiou, G M ^a,b   Paterakis, K ^a   Dardiotis, E ^a   Dardioti, M ^a   Aggelakis, K ^a   Tasiou, A ^a   Xiromerisiou, G ^a   Komnos, A ^b   Zintzaras, E ^b   Scarmeas, N ^c   Papadimitriou, A ^a   Karantanas, A ^b  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN INJURY; CALCULATION; CONFIDENCE INTERVAL; DISEASE COURSE; FEMALE; GENE; GENOTYPE; GLASGOW COMA SCALE; GLASGOW OUTCOME SCALE; HUMAN; IL 1B GENE; IL 1RN GENE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEUROSURGERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANKIN SCALE; STANDARD; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

EID: 26444586705     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000178890.93795.0e     Document Type: Article

References (59)

1. Gennarelli TA, Spielman GM, Langfitt TW et al. Influence of the type of intracranial lesion on outcome from severe head injury. J Neurosurg 1982;56:26-32.
2. Ono J, Yamaura A, Kubota M et al. Outcome prediction in severe head injury: analyses of clinical prognostic factors. J Clin Neurosci 2001;8: 120-123.
3. Paterakis K, Karantanas AH, Komnos A, Volikas Z. Outcome of patients with diffuse axonal injury: the significance and prognostic value of MRI in the acute phase. J Trauma 2000;49:1071-1075.
4. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001;2:734-744.
5. Lenzlinger PM, Morganti-Kossmann MC, Laurer HL, Mclntosh TK. The duality of the inflammatory response to traumatic brain injury. Mol Neurobiol 2001;24:169-181.
6. Schmidt OI, Morganti-Kossmann MC, Heyde CE et al. Tumor necrosis factor-mediated inhibition of interleukin-18 in the brain: a clinical and experimental study in head-injured patients and in a murine model of closed head injury. J Neuroinflammation 2004;1:13.
7. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323-340.
8. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-310.
9. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2394-2400.
10. Tarlow JK, Blakemore AI, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-404.
11. Hall SK, Perregaux DG, Gabel CA et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum 2004;50:1976-1983.
12. Kantarci OH, Atkinson EJ, Hebrink DD et al. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000;106:220-227.
13. McGeer PL, Yasojima K, McGeer EG. Association of interleukin-1 beta polymorphisms with idiopathic Parkinson's disease. Neurosci Lett 2002;326:67-69.
14. Mann CL, Davies MB, Stevenson VL et al. Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity. J Neuroimmunol 2002;129:197-204.
15. McClain CJ, Cohen D, Ott L et al. Ventricular fluid interleukin-1 activity in patients with head injury. J Lab Clin Med 1987;110:48-54.
16. Holmin S, Hojeberg B. In situ detection of intracerebral cytokine expression after human brain contusion. Neurosci Lett 2004;369:108-114.
17. Frati A, Salvati M, Mainiero F et al. Inflammation markers and risk factors for recurrence in 35 patients with a posttraumatic chronic subdural hematoma: a prospective study. J Neurosurg 2004;100:24-32.
18. Joseph L, Fink LM, Hauer-Jensen M. Cytokines in coagulation and thrombosis: a preclinical and clinical review. Blood Coagul Fibrinolysis 2002;13:105-116.
19. Nicklin MJ, Hughes DE, Barton JL et al. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000; 191:303-312.
20. Liaquat I, Dunn LT, Nicoll JA et al. Effect of apolipoprotein E genotype on hematoma volume after trauma. J Neurosurg 2002;96:90-96.
21. Teasdale G, Murray G, Parker L, Jennett B. Adding up the Glasgow Coma Score. Acta Neurochir (Suppl) [Wien] 1979;28:13-16.
22. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997;350:1069-1071.
23. Paterniti S, Falcone MF, Fiore P et al. Is the size of an epidural haematoma related to outcome? Acta Neurochir [Wien] 1998;140:953-955.
24. Gebel JM, Sila CA, Sloan MA et al. Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. Stroke 1998;29:1799-1801.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
27. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975;1:480-484.
28. de Haan R, Limburg M, Bossuyt P et al. The clinical meaning of Rankin "handicap" grades after stroke. Stroke 1995;26:2027-2030.
29. Lawton MT, Du R, Tran MN. et al. Effect of presenting hemorrhage on outcome after microsurgical resection of brain arteriovenous malformations. Neurosurgery 2005;56:485-493.
30. di Giovine FS, Takhsh E, Blakemore AI, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet 1992;1:450.
31. Weir B. Data analysis II: methods for discrete population genetic data. Sunderland, MA: Sinauer Associates, 1996.
32. Nathoo N, Chetty R, van Dellen JR, Barnett GH. Genetic vulnerability following traumatic brain injury: the role of apolipoprotein E. Mol Pathol 2003;56:132-136.
33. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol 1998;47:195-198.
34. Carter DB, Deibel MR, Jr, Dunn CJ et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990;344:633-638.
35. Haskill S, Martin G, Van LeL et al. cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium. Proc Natl Acad Sci USA 1991;88:3681-3685.
36. Wang CX, Shuaib A. Involvement of inflammatory cytokines in central nervous system injury. Prog Neurobiol 2002;67:161-172.
37. Francis SE, Camp NJ, Dewberry RM et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999;99:861-866.
38. Worrall BB, Azhar S, Nyquist PA et al. Interleukin-1 receptor antagonist gene polymorphisms in carotid atherosclerosis. Stroke 2003;34: 790-793.
39. Kastrati A, Koch W, Berger PB et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000;36:2168-2173.
40. Schorer AE, White JG. Interleukin 1 enhances arterial thrombogenicity in vitro. Thromb Res 1989;56:515-522.
41. Bochner BS, Luscinskas FW, Gimbrone Jr. MA, et al. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:1553-1557.
42. Grames M, Breviario F, Pintucci G et al. Enhancement by interleukin-1 (IL-1) of plasminogen activator inhibitor (PA-I) activity in cultured human endothelial cells. Biochem Biophys Res Commun 1986;139:720-727.
43. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003;7:23-38.
44. Osnes LT, Westvik AB, Joo GB et al. Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13. Cytokine 1996;8:822-827.
45. Lindemann S, Tolley ND, Dixon DA et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154:485-490.
46. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol 2004;25:536-542.
47. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988;8:5588-5592.
48. Stein DM, Dutton RP. Uses of recombinant factor VIIa in trauma. Curr Opin Crit Care 2004;10:520-528.
49. Udekwu P, Kromhout-Schiro S, Vaslef S et al. Glasgow Coma Scale score, mortality, and functional outcome in head-injured patients. J Trauma 2004;56:1084-1089.
50. Wilson JT. Assessing outcome in head injury trials. Curr Pharm Des 2001;7:1537-1552.
51. Pettigrew LE, Wilson JT, Teasdale GM. Assessing disability after head injury: improved use of the Glasgow Outcome Scale. J Neurosurg 1998; 89:939-943.
52. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 1999;10:119-130.
53. Tehranian R, Andell-Jonsson S, Beni SM et al. Improved recovery and delayed cytokine induction after closed head injury in mice with central overexpression of the secreted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 2002;19:939-951.
54. Giulian D, Woodward J, Young DG et al. Interleukin-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci 1988;8:2485-2490.
55. Herx LM, Rivest S, Yong VW. Central nervous system-initiated inflammation and neurotrophism in trauma: IL-1 beta is required for the production of ciliary neurotrophic factor. J Immunol 2000;165:2232-2239.
56. Rhodes JK. Actions of glucocorticoids and related molecules after traumatic brain injury. Curr Opin Crit Care 2003;9:86-91.
57. Bird TD, Jarvik GP, Wood NW. Genetic association studies: genes in search of diseases. Neurology 2001;57:1153-1154.
58. Ott J. Association of genetic loci: replication or not, that is the question. Neurology 2004;63:955-958.
59. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999;55:997-1004.